Claims for Patent: 9,402,916

Summary for Patent: 9,402,916

Title:	Re-directed immunotherapy
Abstract:	The invention provides an agent for preventing or treating a condition characterized by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.
Inventor(s):	Cobbold; Mark (Birmingham, GB), Millar; David (Birmingham, GB)
Assignee:	THE UNIVERSITY OF BIRMINGHAM (Birmingham, GB)
Application Number:	14/005,452
Patent Claims:	1. A method of retargeting T cells to cancer cells, the method comprising administering an agent for treating cancer to a human subject in need thereof, wherein the agent comprises: i) a targeting moiety that is capable of targeting to the cancer cells, wherein the targeting moiety is an antibody or antigen binding fragment thereof that binds a tumor antigen; and ii) a viral T cell epitope that elicits an existing immune response in the subject and binds to a HLA molecule on the surface of the cancer cell of the human subject and has a HLA matched to the subject, and iii) a peptide linker comprising a peptide cleavage site cleavable by a tumor associated protease and wherein the linker can be selectively cleaved by the tumor associated protease to release the T cell epitope in the vicinity of, and outside of, the cancer cell. 2. The method according to claim 1, further comprising determining any one of (i) HLA alleles of the subject, (ii) cytotoxic T cell response of the subject to a T cell epitope (iii) expression profile of the cancer cell in the subject. 3. The method according to claim 1, further comprising administering a therapeutic agent suitable for treating cancer. 4. The method of claim 1, wherein the antibody is Rituximab or Cetuximab. 5. The method of claim 1, wherein the T cell epitope is a peptide from Varicella Zoster virus, Herpes simplex virus, cytomegalovirus, Epstein Barr virus, adenovirus, rhinovirus, or influenza virus. 6. The method of claim 1, wherein the T cell epitope is a cytomegalovirus peptide. 7. The method of claim 1, wherein the T cell epitope is NLVPMVATV (SEQ ID NO: 21), TPRVTGGGAM (SEQ ID NO: 31), DYSNTHSTRYV (SEQ ID NO: 55), YVLEETSVM (SEQ ID NO: 3), or VLEETSVML (SEQ ID NO: 4). 8. The method of claim 1, wherein the T cell epitope is NLVPMVATV (SEQ ID NO: 21). 9. The method of claim 1, wherein the antibody or antigen binding fragment thereof is specific for any of Her2/Neu; CD22; EpCAM (CD326); EGFR; PMSA; CD30; CD20; CD33; membrane IgE; IgE Receptor (CD23), CD80; CD86; CD2; CA125; Carbonic Anhydrase IX; CD70; CD74; CD56; CD40; CD19; c-met/HGFR; TRAIL-R1; DR5; PD-1; PD1L; IGF-1R; VEGF-R2; Prostate stem cell antigen (PSCA); MUC1; CanAg; Mesothelin; P-cadherin; Myostatin (GDF8); Cripto (TDGF1); ACVRL1/ALK1; MUC5AC; CEACAM; SLC44A4; CD2/CS1; CD137; CXCR4; Neuropilin 1; Glypican; HER3/EGFR; PDGFRa, EphA2, CD22, E-cadherin, FGFR3, and CD138. 10. The method of claim 1, wherein the antibody or antigen binding fragment thereof binds to CD20 or EGFR and the T cell epitope is a cytomegalovirus peptide. 11. The method of claim 10, wherein the T cell epitope is NLVPMVATV (SEQ ID NO: 21). 12. The method of claim 1, wherein the tumor associated protease is a cysteine protease, an aspartyl protease, a serine protease, or a metalloprotease. 13. The method of claim 1, wherein the tumor associated protease is Cathepsin B, Cathepsin L, Cathepsin S, Cathepsin D, Cathepsin E, Cathepsin A, Cathepsin G, Thrombin, Plasmin, Urokinase, Tissue Plasminogen Activator, Metalloproteinase 1 (MMP1), MMP2, MMP3, MMP4, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP20, MMP21, MMP23, MMP24, MMP25, MMP26, MMP28, ADAM, ADAMTS, CD10 (CALLA), or prostate specific antigen. 14. The method of claim 1, wherein the tumor associated protease is a metalloprotease or a cathepsin. 15. The method of claim 1, wherein the tumor associated protease is MMP2, ADAM28, or Cathepsin B. 16. The method of claim 11, wherein the tumor associated protease is ADAM28. 17. The method of claim 1, wherein the T cell epitope is an MHC Class I restricted antigen, an MHC Class II restricted antigen, or an antigen that is capable of binding to a group I CD1 molecule.

Details for Patent 9,402,916

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2031-03-17
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2031-03-17
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2031-03-17
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2031-03-17
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2031-03-17